Clinical trial
A Dose Ranging Study Of GW640385 Boosted With Ritonavir (Rtv) In Comparison To A…
NCT00242879 · ViiV Healthcare, Industry · Terminated
Key facts
| NCT number | NCT00242879 |
|---|---|
| Title | A Dose Ranging Study Of GW640385 Boosted With Ritonavir (Rtv) In Comparison To A RTV-Boosted Protease Inhibitor (PI) In HIV-1 Infected PI-Experienced Adults |
| Official title | Phase IIB, Randomized, Multicenter, Parallel Group, Study to Evaluate the Safety, Pharmacokinetics and Antiviral Effect of Four Blinded Dosing Regimens of GW640385X/Ritonavir Compared to Open-label Current PI Therapy in HIV-1 Infected, Protease Inhibitor Experienced Adults for 2 Weeks With Long-term… |
| Lead sponsor | ViiV Healthcare, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Infection, Human Immunodeficiency Virus I, HIV-1 Infection |
| Intervention type | Drug |
| Interventions | Physician determined comparator PI + ritonavir, GW640385 + ritonavir |
| Enrollment | 130 |
| Start date | Aug 1, 2005 |
| Primary completion | Jun 1, 2007 |
| Completion | Jun 1, 2007 |
| First posted | Oct 21, 2005 |
| Last update posted | May 30, 2017 |
| Countries | Australia, Belgium, Canada, France, Germany, Italy, Portugal, Puerto Rico, Romania, United Kingdom, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: